Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00124059 · ClinicalTrials.gov registry record · Phase 3

Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.

A Phase 3 study of Alcoholism, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 3
Development phase
61
Enrollment target
1
Study location

NCT00124059 is a Phase 3 study of Alcoholism that has completed, run by University of Pennsylvania. The registered enrollment target is 61 participants, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00124059, a Phase 3 study of Alcoholism, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 3
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether seroquel is effective in the treatment of type A and type B alcohol dependence.

Conditions Studied

Alcoholism

Interventions

  • DRUG Placebo
  • DRUG Seroquel

Study Locations (1)

Pennsylvania

  • University of Pennsylvania Treatment Research Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2003-03
Est. Completion 2005-10
Phase Phase 3

Sponsor

University of Pennsylvania

1,423 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00124059

The ClinicalTrials.gov registry entry for NCT00124059 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (84% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00124059 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00124059 about?

NCT00124059 is a clinical study titled "Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.". The purpose of this study is to determine whether seroquel is effective in the treatment of type A and type B alcohol dependence.

What is the current status of trial NCT00124059?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 61 participants. The study started on 2003-03. Estimated completion is 2005-10.

What conditions does trial NCT00124059 study?

This clinical trial studies the following conditions: Alcoholism.

What interventions are being tested in trial NCT00124059?

The interventions under investigation include: Placebo (DRUG), Seroquel (DRUG).

Who is sponsoring clinical trial NCT00124059?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00124059 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alcoholism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alcoholism

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.